| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-04-28 06:03:40 UTC |
|---|
| Updated at | 2022-04-28 06:03:40 UTC |
|---|
| NP-MRD ID | NP0061172 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | 3'-Hydroxy-3,4,4'5-tetramethoxystilbene |
|---|
| Description | Combretastatin A4, also known as CA4DP or CRC 87-09, belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. 3'-Hydroxy-3,4,4'5-tetramethoxystilbene is found in Combretum caffrum. 3'-Hydroxy-3,4,4'5-tetramethoxystilbene was first documented in 2021 (PMID: 34371485). Based on a literature review a significant number of articles have been published on Combretastatin A4 (PMID: 34342437) (PMID: 35139789) (PMID: 35104671) (PMID: 35026565) (PMID: 34970997) (PMID: 34959731). |
|---|
| Structure | COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1O InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5- |
|---|
| Synonyms | | Value | Source |
|---|
| 1-(3,4,5-Trimethoxyphenyl)-2-(3'-hydroxy-4'-methoxyphenyl)ethene | MeSH | | 2-Methoxy-5-((Z)-2-(3,4,5-trimethoxyphenyl)vinyl)phenyl dihydrogen phosphate | MeSH | | 3,4,5-Trimethoxy-3'-hydroxy-4'-methoxystilbene | MeSH | | CA4dp | MeSH | | CRC 87-09 | MeSH | | CRC-98-09 | MeSH | | Combretastatin a-4 | MeSH | | Combretastatin a-4 disodium phosphate | MeSH | | Combretastatin a4 phosphate | MeSH | | Deoxycombretastatin a-4 | MeSH | | Fosbretabulin | MeSH | | Isocombretastatin a-4 | MeSH | | Phenol, 2-methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-,1-(dihydrogen phosphate) | MeSH | | Phenol, 2-methoxy-5-((Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, dihydrogen phosphate | MeSH |
|
|---|
| Chemical Formula | C18H20O5 |
|---|
| Average Mass | 316.3530 Da |
|---|
| Monoisotopic Mass | 316.13107 Da |
|---|
| IUPAC Name | 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol |
|---|
| Traditional Name | combretastatin A-4 |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1O |
|---|
| InChI Identifier | InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5- |
|---|
| InChI Key | HVXBOLULGPECHP-WAYWQWQTSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Phenylpropanoids and polyketides |
|---|
| Class | Stilbenes |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Stilbenes |
|---|
| Alternative Parents | |
|---|
| Substituents | - Stilbene
- Methoxyphenol
- Phenoxy compound
- Anisole
- Methoxybenzene
- Styrene
- Phenol ether
- 1-hydroxy-4-unsubstituted benzenoid
- 1-hydroxy-2-unsubstituted benzenoid
- Alkyl aryl ether
- Phenol
- Benzenoid
- Monocyclic benzene moiety
- Ether
- Organooxygen compound
- Hydrocarbon derivative
- Organic oxygen compound
- Aromatic homomonocyclic compound
|
|---|
| Molecular Framework | Aromatic homomonocyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Li YH, Lu JQ, Deng XW, Wang X, Jia F, Zhong SH, Cui XY, Pan ZA, Shao LH, Wu Y: Self-assembling Combretastatin A4 Incorporated Protamine/Nanodiamond Hybrids for Combined Anti-angiogenesis and Mild Photothermal Therapy in Liver Cancer. Nanotechnology. 2021 Aug 9. doi: 10.1088/1361-6528/ac1be0. [PubMed:34371485 ]
- Schmidt C, Babu T, Kostrhunova H, Timm A, Basu U, Ott I, Gandin V, Brabec V, Gibson D: Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs? J Med Chem. 2021 Aug 12;64(15):11364-11378. doi: 10.1021/acs.jmedchem.1c00706. Epub 2021 Aug 3. [PubMed:34342437 ]
- Cao Y, Ahmed AMQ, Du HH, Sun W, Lu X, Xu Z, Tao J, Cao QR: Combretastatin A4-loaded Poly (Lactic-co-glycolic Acid)/Soybean Lecithin Nanoparticles with Enhanced Drug Dissolution Rate and Antiproliferation Activity. Curr Drug Deliv. 2022 Aug 6;19(9):918-927. doi: 10.2174/1567201819666220209093443. [PubMed:35139789 ]
- Poojari R, Mohanty B, Kadwad V, Suryawanshi D, Chaudhari P, Khade B, Srivastava R, Gupta S, Panda D: Combinatorial cetuximab targeted polymeric nanocomplexes reduce PRC1 level and abrogate growth of metastatic hepatocellular carcinoma in vivo with efficient radionuclide uptake. Nanomedicine. 2022 Apr;41:102529. doi: 10.1016/j.nano.2022.102529. Epub 2022 Jan 30. [PubMed:35104671 ]
- Liu Y, Deng F, Zheng R, Chen X, Zhao L, Yu B, Chen A, Jiang X, Cheng H, Li S: Self-delivery nanomedicine for vascular disruption-supplemented chemo-photodynamic tumor therapy. J Colloid Interface Sci. 2022 Apr 15;612:562-571. doi: 10.1016/j.jcis.2021.12.128. Epub 2021 Dec 24. [PubMed:35026565 ]
- Rahman KMM, Thapa P, Hurst R, Woo S, You Y: Singlet Oxygen Activatable Prodrugs of Paclitaxel, SN-38, MMC and CA4: Nonmitochondria-Targeted Prodrugs. Photochem Photobiol. 2022 Mar;98(2):389-399. doi: 10.1111/php.13589. Epub 2022 Jan 11. [PubMed:34970997 ]
- Atanasov G, Rusew RI, Gelev VM, Chanev CD, Nikolova R, Shivachev BL, Petrov OI, Apostolova MD: New Heterocyclic Combretastatin A-4 Analogs: Synthesis and Biological Activity of Styryl-2(3H)-benzothiazolones. Pharmaceuticals (Basel). 2021 Dec 20;14(12):1331. doi: 10.3390/ph14121331. [PubMed:34959731 ]
- Mirzavi F, Barati M, Vakili-Ghartavol R, Roshan MK, Mashreghi M, Soukhtanloo M, Jaafari MR: Pegylated liposomal encapsulation improves the antitumor efficacy of combretastatin A4 in murine 4T1 triple-negative breast cancer model. Int J Pharm. 2022 Feb 5;613:121396. doi: 10.1016/j.ijpharm.2021.121396. Epub 2021 Dec 20. [PubMed:34942328 ]
- Paidakula S, Nerella S, Kankala S, Kankala RK: Recent Trends in Tubulin-Binding Combretastatin A-4 Analogs for Anticancer Drug Development. Curr Med Chem. 2022;29(21):3748-3773. doi: 10.2174/0929867328666211202101641. [PubMed:34856892 ]
- Zhong Y, Zhang L, Sun S, Zhou Z, Ma Y, Hong H, Yang D: Sequential drug delivery by injectable macroporous hydrogels for combined photodynamic-chemotherapy. J Nanobiotechnology. 2021 Oct 23;19(1):333. doi: 10.1186/s12951-021-01066-1. [PubMed:34688292 ]
- Yu X, Su Q, Chang X, Chen K, Yuan P, Liu T, Tian R, Bai Y, Zhang Y, Chen X: Multimodal obstruction of tumorigenic energy supply via bionic nanocarriers for effective tumor therapy. Biomaterials. 2021 Nov;278:121181. doi: 10.1016/j.biomaterials.2021.121181. Epub 2021 Oct 9. [PubMed:34653932 ]
- Zhang R, Cheng G, Liu S, Lv H, Li J: A four-in-one pure nanomedicine for synergistic multi-target therapy against breast cancer. J Mater Chem B. 2021 Nov 3;9(42):8809-8822. doi: 10.1039/d1tb01820e. [PubMed:34633023 ]
- Dai G, Zheng D, Liu G, Song Q: Synergistic Anticancer Effects of Cisplatin Combined with Combretastatin A4 Phosphate on Human Osteosarcoma-Xenografted Mice. Cells Tissues Organs. 2021;210(4):293-300. doi: 10.1159/000517446. Epub 2021 Aug 25. [PubMed:34433168 ]
|
|---|